subscribeSubscribe
price-trendAsk Us
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
BUSINESSWIRE
03 Aug 2022
Share Share
GSK side-lines COVID drug otilimab to focus on Xevudy

GSK side-lines COVID drug otilimab to focus on Xevudy
Phil Taylor PHARMAPHORUM
28 Oct 2021
Share Share
GSK to amend Covid-19 study to confirm efficacy in older patients

GSK to amend Covid-19 study to confirm efficacy in older patients
CLINICALTRIALSARENA
25 Feb 2021
Share Share
Anti-inflammatory and cancer drugs tested in UK as possible COVID-19 therapy

Anti-inflammatory and cancer drugs tested in UK as possible COVID-19 therapy
Paul Sandle ECONOMICTIMES
11 Jun 2020
Share Share
Hydroxychloroquine fails to show benefit in Covid-19 study

Hydroxychloroquine fails to show benefit in Covid-19 study
CLINICALTRIALSARENA
08 May 2020
Share Share
GSK to test experimental drug to treat pneumonia from COVID-19

GSK to test experimental drug to treat pneumonia from COVID-19
REUTERS
07 May 2020
Share Share
GSK launches PhIII programme for otilimab in RA

GSK launches PhIII programme for otilimab in RA
Selina McKee PHARMATIMES
06 Jul 2019
Share Share